LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Elenco Azioni・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

708.02 -1.74

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

705.44

Massimo

723.68

Metriche Chiave
By Trading Economics
Entrata	-117M 727M
Vendite	-279M 3.6B
P/E Media del settore	17.122 49.8
EPS	9.47
Rendimento da dividendi	0.51
Margine di Profitto	20.17
Dipendenti	15,343
EBITDA	-234M 967M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+22.23% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	0.51% 2.25%
Utili prossimi	31 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-3.7B 74B
Apertura precedente	709.76
Chiusura precedente	708.02

Notizie sul Sentiment di mercato

By Acuity

25%

75%

55 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

542.44 / 599.76 Supporto e resistenza

Regeneron Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 ago 2025, 11:33 UTC

Utili

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

29 apr 2026, 12:01 UTC

Utili

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

23 apr 2026, 21:48 UTC

Acquisizioni, Fusioni, Takeovers

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

11 mar 2026, 11:02 UTC

Discorsi di Mercato

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

14 dic 2025, 08:30 UTC

Acquisizioni, Fusioni, Takeovers

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

1 ago 2025, 13:16 UTC

Utili

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 ago 2025, 12:40 UTC

Utili

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 ago 2025, 10:41 UTC

Utili

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

1 ago 2025, 10:41 UTC

Utili

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

1 ago 2025, 10:40 UTC

Utili

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

1 ago 2025, 10:38 UTC

Utili

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

1 ago 2025, 10:37 UTC

Utili

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

1 ago 2025, 10:35 UTC

Utili

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

1 ago 2025, 10:34 UTC

Utili

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

1 ago 2025, 10:33 UTC

Utili

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

1 ago 2025, 10:32 UTC

Utili

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

1 ago 2025, 10:31 UTC

Utili

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

1 ago 2025, 10:31 UTC

Utili

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

1 ago 2025, 10:30 UTC

Utili

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

1 ago 2025, 10:30 UTC

Utili

Regeneron Pharma 2Q Rev $3.68B >REGN

1 ago 2025, 10:30 UTC

Utili

Regeneron Pharma 2Q EPS $12.81 >REGN

1 ago 2025, 10:30 UTC

Utili

Regeneron Pharma 2Q Net $1.39B >REGN

13 giu 2025, 21:42 UTC

Acquisizioni, Fusioni, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 giu 2025, 20:45 UTC

Acquisizioni, Fusioni, Takeovers

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 giu 2025, 20:34 UTC

Acquisizioni, Fusioni, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 giu 2025, 20:14 UTC

Acquisizioni, Fusioni, Takeovers

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 giu 2025, 20:14 UTC

Acquisizioni, Fusioni, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 giu 2025, 20:14 UTC

Acquisizioni, Fusioni, Takeovers

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

5 giu 2025, 01:41 UTC

Acquisizioni, Fusioni, Takeovers

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30 mag 2025, 08:58 UTC

Azioni calde

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

Confronto tra pari

Modifica del prezzo

Regeneron Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

22.23% in crescita

Previsioni per 12 mesi

Media 881.33 USD 22.23%

Alto 1,057 USD

Basso 762 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Regeneron Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

19 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 19 che hanno fornito valutazioni azionarie a Regeneron Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

542.44 / 599.76Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

55 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.